Literature DB >> 9812900

Reovirus therapy of tumors with activated Ras pathway.

M C Coffey1, J E Strong, P A Forsyth, P W Lee.   

Abstract

Human reovirus requires an activated Ras signaling pathway for infection of cultured cells. To investigate whether this property can be exploited for cancer therapy, severe combined immune deficient mice bearing tumors established from v-erbB-transformed murine NIH 3T3 cells or human U87 glioblastoma cells were treated with the virus. A single intratumoral injection of virus resulted in regression of tumors in 65 to 80 percent of the mice. Treatment of immune-competent C3H mice bearing tumors established from ras-transformed C3H-10T1/2 cells also resulted in tumor regression, although a series of injections were required. These results suggest that, with further work, reovirus may have applicability in the treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9812900     DOI: 10.1126/science.282.5392.1332

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  229 in total

1.  Reovirus as a novel oncolytic agent.

Authors:  K L Norman; P W Lee
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

2.  When two is better than one: thoughts on three decades of interaction between Virology and the Journal of Virology.

Authors:  W K Joklik
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

3.  Recombinant measles viruses efficiently entering cells through targeted receptors.

Authors:  U Schneider; F Bullough; S Vongpunsawad; S J Russell; R Cattaneo
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 4.  Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates.

Authors:  Guido Wollmann; Koray Ozduman; Anthony N van den Pol
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

5.  MAPK signal-integrating kinase controls cap-independent translation and cell type-specific cytotoxicity of an oncolytic poliovirus.

Authors:  Christian Goetz; Richard G Everson; Linda C Zhang; Matthias Gromeier
Journal:  Mol Ther       Date:  2010-07-20       Impact factor: 11.454

6.  A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report.

Authors:  E Anders Kolb; Valerie Sampson; Deborah Stabley; Alexa Walter; Katia Sol-Church; Timothy Cripe; Pooja Hingorani; Charlotte Hsieh Ahern; Brenda J Weigel; James Zwiebel; Susan M Blaney
Journal:  Pediatr Blood Cancer       Date:  2015-02-27       Impact factor: 3.167

7.  NKp46 Recognizes the Sigma1 Protein of Reovirus: Implications for Reovirus-Based Cancer Therapy.

Authors:  Yotam Bar-On; Yoav Charpak-Amikam; Ariella Glasner; Batya Isaacson; Alexandra Duev-Cohen; Pinchas Tsukerman; Alexander Varvak; Michal Mandelboim; Ofer Mandelboim
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

Review 8.  Reovirus: a targeted therapeutic--progress and potential.

Authors:  Radhashree Maitra; Mohammad H Ghalib; Sanjay Goel
Journal:  Mol Cancer Res       Date:  2012-10-04       Impact factor: 5.852

9.  Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults.

Authors:  Kimberly P Kicielinski; E Antonio Chiocca; John S Yu; George M Gill; Matt Coffey; James M Markert
Journal:  Mol Ther       Date:  2014-02-20       Impact factor: 11.454

10.  Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2.

Authors:  Timothy Kottke; Jill Thompson; Rosa Maria Diaz; Jose Pulido; Candice Willmon; Matt Coffey; Peter Selby; Alan Melcher; Kevin Harrington; Richard G Vile
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.